<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575415</url>
  </required_header>
  <id_info>
    <org_study_id>CTONG1905</org_study_id>
    <nct_id>NCT04575415</nct_id>
  </id_info>
  <brief_title>Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study</brief_title>
  <acronym>BELLA</acronym>
  <official_title>Bevacizumab Plus EGFR Tyrosine Kinase Inhibitors in Chinese Patients With Stage IIIB-IV EGFR-mutant Non-small Cell Lung Cancer: a Prospective,Multicenter, Non-interventional,Real-world Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Association of Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Association of Clinical Trials</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multicenter, real-world study to investigate the efficacy and&#xD;
      safety of bevacizumab plus epidermal growth factor (EGFR) Tyrosine Kinase Inhibitors in&#xD;
      Chinese Patients With Stage IIIB/IV EGFR-mutant Non-small Cell Lung Cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) for bevacizumab plus first-generation EGFR-TKIs by investigator using RECIST v1.1</measure>
    <time_frame>This is a real-world study. The estimated median PFS for bevacizumab plus first-generation EGFR-TKIs is 18 months according to previous data.</time_frame>
    <description>To evaluate the efficacy of bevacizumab combined with first-generation EGFR-TKIs in patients with EGFR-mutant NSCLC as measured by investigators</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) for bevacizumab plus second-generation EGFR-TKIs by investigator using RECIST v1.1</measure>
    <time_frame>This is a real-world study. The estimated median PFS for bevacizumab plus second-generation EGFR-TKIs is 20 months according to previous data.</time_frame>
    <description>To evaluate the efficacy of bevacizumab combined with second-generation EGFR-TKIs in patients with EGFR-mutant NSCLC as measured by investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) for bevacizumab plus third-generation EGFR-TKIs by investigator using RECIST v1.1</measure>
    <time_frame>This is a real-world study. The estimated median PFS for bevacizumab plus third-generation EGFR-TKIs is 22 months according to previous data.</time_frame>
    <description>To evaluate the efficacy of bevacizumab combined with third-generation EGFR-TKIs in patients with EGFR-mutant NSCLC as measured by investigators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) by investigator using RECIST v1.1</measure>
    <time_frame>Baseline overall tumor assessment can be performed up to 28 days after the first-dose of treatment. Post-baseline assessment will be performed every six weeks until 1st disease progression, through study completion, an average of 2 years.</time_frame>
    <description>To evaluate the efficacy of bevacizumab combined with EGFR-TKIs in patients with NSCLC harbouring activating EGFR mutations, with or without EGFR T790M mutation,as measured by investigators assessed objective response rate using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) by investigator using RECIST v1.1</measure>
    <time_frame>Baseline overall tumor assessment can be performed up to 28 days after the first-dose of treatment. Post-baseline assessment will be performed every six weeks until 1st disease progression, through study completion, an average of 2 years.</time_frame>
    <description>Disease control rate (DCR) will be analyzed using similar method as objective response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>The primary analysis on overall survival is espected to perform on 48 months of follow-up.</time_frame>
    <description>To evaluate the efficacy of bevacizumab combined with EGFR-TKIs in patients with NSCLC harbouring activating EGFR mutations,with or without EGFR T790M mutation,as measured by investigators assessed overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events using CTCAE V5.0</measure>
    <time_frame>This is a real-world study. Safety of the combination treatment is expected to perform until the study completion, an average of 1.5 years,according to CTCAE V5.0.</time_frame>
    <description>To evaluate the incidence of Treatment-Emergent Adverse Events of bevacizumab combined with EGFR-TKIs in patients with NSCLC harbouring activating EGFR mutations,with or without EGFR T790M mutation.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">272</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Arm 1:Bevacizumab plus Erlotinib/Gefitinib/Icotinib</arm_group_label>
    <description>Patients with EGFR-mutant NSCLC would receive bevacizumab plus first-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Erlotinib 150 mg tablets once daily or Gefitinib 250mg once daily or Icotinib 125mg three times a day would be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2:Bevacizumab plus Afatinib/Dacomitinib</arm_group_label>
    <description>Patients with EGFR-mutant NSCLC would receive bevacizumab plus second-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks.Afatinib 40 mg or clinical routine dose once daily or Dacomitinib 45mg or clinical routine dose once daily or clinical routine dose would be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3:Bevacizumab plus Osimertinib</arm_group_label>
    <description>Patients with EGFR-mutant NSCLC would receive bevacizumab plus third-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Osimertinib 80 mg tablets once daily would be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 15mg/kg or clinical routine dose by intravenous drip infusion on day 1 of a 21-day cycle</description>
    <arm_group_label>Arm 1:Bevacizumab plus Erlotinib/Gefitinib/Icotinib</arm_group_label>
    <arm_group_label>Arm 2:Bevacizumab plus Afatinib/Dacomitinib</arm_group_label>
    <arm_group_label>Arm 3:Bevacizumab plus Osimertinib</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150mg, orally once a day</description>
    <arm_group_label>Arm 1:Bevacizumab plus Erlotinib/Gefitinib/Icotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>Gefitinib 250mg, orally once a day</description>
    <arm_group_label>Arm 1:Bevacizumab plus Erlotinib/Gefitinib/Icotinib</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib</intervention_name>
    <description>Icotinib 125mg three times a day</description>
    <arm_group_label>Arm 1:Bevacizumab plus Erlotinib/Gefitinib/Icotinib</arm_group_label>
    <other_name>Conmana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Afatinib 40 mg or clinical routine dose once daily</description>
    <arm_group_label>Arm 2:Bevacizumab plus Afatinib/Dacomitinib</arm_group_label>
    <other_name>Gilotrif</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacomitinib</intervention_name>
    <description>Dacomitinib 45mg or clinical routine dose once daily</description>
    <arm_group_label>Arm 2:Bevacizumab plus Afatinib/Dacomitinib</arm_group_label>
    <other_name>Vizimpro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Osimertinib 80 mg once daily</description>
    <arm_group_label>Arm 3:Bevacizumab plus Osimertinib</arm_group_label>
    <other_name>Tagrisso</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Histologically or cytologically documented inoperable, locally advanced (Stage IIIB, IIIC)&#xD;
        or metastatic (Stage IV) non-squamous NSCLC with EGFR exon 19 deletion or/and exon 21L858R&#xD;
        mutation, with or without EGFR T790M mutation, who meet the inclusion criteria will be&#xD;
        enrolled in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must meet the following criteria for study entry:&#xD;
&#xD;
               1. Signed Informed Consent Form.&#xD;
&#xD;
               2. Age≥18 years.&#xD;
&#xD;
               3. Histologically or cytologically documented inoperable, locally advanced (Stage&#xD;
                  IIIB, IIIC), metastatic (Stage IV) or recurrent non-squamous NSCLC.&#xD;
&#xD;
               4. An exon 19 deletion mutation or exon 21 L858R mutation in EGFR has been found&#xD;
                  clinically, with or without EGFR T790M mutation&#xD;
&#xD;
               5. Eastern Cooperative Oncology Group performance status 0-2 or KPS ≥60&#xD;
&#xD;
               6. Previous EGFR-TKIs or anti-angiogenic agents or systemic cytotoxic chemotherapy&#xD;
                  for locally advanced, metastatic or recurrent disease has not been performed.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Patients who meet any of the following criteria will be excluded from study entry:&#xD;
&#xD;
               1. Squamous carcinoma or mixed non-small cell lung cancer with squamous component.&#xD;
&#xD;
               2. Potential hazard for receiving EGFR-TKIs or bevacizumab by clinical evaluations&#xD;
&#xD;
               3. Previous history of receiving EGFR-TKIs or bevacizumab treatment prior to study&#xD;
                  enrollment&#xD;
&#xD;
               4. Suspected or diagnosed leptomeningeal metastases&#xD;
&#xD;
               5. Chest radiotherapy within 3 months prior to study enrollment&#xD;
&#xD;
               6. Open surgery within 4 weeks prior to study enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qing Zhou, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qing Zhou, PhD</last_name>
    <phone>862081884713</phone>
    <phone_ext>80611</phone_ext>
    <email>gzzhouqing@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chongrui Xu, PhD</last_name>
    <phone>862081884713</phone>
    <phone_ext>80611</phone_ext>
    <email>xucr001@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Zhou, PhD</last_name>
      <phone>862081884713</phone>
      <phone_ext>80611</phone_ext>
      <email>gzzhouqing@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 17, 2020</last_update_submitted>
  <last_update_submitted_qc>October 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Afatinib</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

